Literature DB >> 21383153

Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.

Jelena Urosevic1, Vincent Sauzeau, María L Soto-Montenegro, Santiago Reig, Manuel Desco, Emma M Burkitt Wright, Marta Cañamero, Francisca Mulero, Sagrario Ortega, Xosé R Bustelo, Mariano Barbacid.   

Abstract

RASopathies are a class of developmental syndromes that result from congenital mutations in key elements of the RAS/RAF/MEK signaling pathway. A well-recognized RASopathy is the cardio-facio-cutaneous (CFC) syndrome characterized by a distinctive facial appearance, heart defects, and mental retardation. Clinically diagnosed CFC patients carry germ-line mutations in four different genes, B-RAF, MEK1, MEK2, and K-RAS. B-RAF is by far the most commonly mutated locus, displaying mutations that most often result in constitutive activation of the B-RAF kinase. Here, we describe a mouse model for CFC generated by germ-line expression of a B-RafLSLV600E allele. This targeted allele allows low levels of expression of B-RafV600E, a constitutively active B-Raf kinase first identified in human melanoma. B-Raf+/LSLV600E mice are viable and display several of the characteristic features observed in CFC patients, including reduced life span, small size, facial dysmorphism, cardiomegaly, and epileptic seizures. These mice also show up-regulation of specific catecholamines and cataracts, two features detected in a low percentage of CFC patients. In addition, B-Raf+/LSLV600E mice develop neuroendocrine tumors, a pathology not observed in CFC patients. These mice may provide a means of better understanding the pathophysiology of at least some of the clinical features present in CFC patients. Moreover, they may serve as a tool to evaluate the potential therapeutic efficacy of B-RAF inhibitors and establish the precise window at which they could be effective against this congenital syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383153      PMCID: PMC3064394          DOI: 10.1073/pnas.1016933108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

2.  Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.

Authors:  A-M Nyström; S Ekvall; E Berglund; M Björkqvist; G Braathen; K Duchen; H Enell; E Holmberg; U Holmlund; M Olsson-Engman; G Annerén; M-L Bondeson
Journal:  J Med Genet       Date:  2008-05-02       Impact factor: 6.318

3.  Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations.

Authors:  C M Armour; J E Allanson
Journal:  J Med Genet       Date:  2007-11-26       Impact factor: 6.318

4.  A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition.

Authors:  Alberto J Schuhmacher; Carmen Guerra; Vincent Sauzeau; Marta Cañamero; Xosé R Bustelo; Mariano Barbacid
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

5.  Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.

Authors:  Pablo Rodriguez-Viciana; Katherine A Rauen
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

6.  Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.

Authors:  Hilde Brems; Magdalena Chmara; Mourad Sahbatou; Ellen Denayer; Koji Taniguchi; Reiko Kato; Riet Somers; Ludwine Messiaen; Sofie De Schepper; Jean-Pierre Fryns; Jan Cools; Peter Marynen; Gilles Thomas; Akihiko Yoshimura; Eric Legius
Journal:  Nat Genet       Date:  2007-08-19       Impact factor: 38.330

7.  Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Authors:  Nathalie Dhomen; Jorge S Reis-Filho; Silvy da Rocha Dias; Robert Hayward; Kay Savage; Veronique Delmas; Lionel Larue; Catrin Pritchard; Richard Marais
Journal:  Cancer Cell       Date:  2009-04-07       Impact factor: 31.743

8.  Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.

Authors:  Xu Chen; Norisato Mitsutake; Krista LaPerle; Nagako Akeno; Pat Zanzonico; Valerie A Longo; Shin Mitsutake; Edna T Kimura; Hartmut Geiger; Eugenio Santos; Hans G Wendel; Aime Franco; Jeffrey A Knauf; James A Fagin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

Review 9.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Opin Genet Dev       Date:  2009-05-19       Impact factor: 5.578

10.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

View more
  28 in total

Review 1.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

Review 2.  Genetically modified laboratory mice with sebaceous glands abnormalities.

Authors:  Carmen Ehrmann; Marlon R Schneider
Journal:  Cell Mol Life Sci       Date:  2016-07-25       Impact factor: 9.261

Review 3.  RAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunction.

Authors:  Jian Zhong
Journal:  Biol Chem       Date:  2016-03       Impact factor: 3.915

4.  Craniofacial and dental development in cardio-facio-cutaneous syndrome: the importance of Ras signaling homeostasis.

Authors:  A F Goodwin; S Oberoi; M Landan; C Charles; J Groth; A Martinez; C Fairley; L A Weiss; W E Tidyman; O D Klein; K A Rauen
Journal:  Clin Genet       Date:  2012-09-27       Impact factor: 4.438

Review 5.  Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders.

Authors:  Steven A Sloan; Ben A Barres
Journal:  Curr Opin Neurobiol       Date:  2014-03-30       Impact factor: 6.627

6.  The sixth international RASopathies symposium: Precision medicine-From promise to practice.

Authors:  Karen W Gripp; Lisa Schill; Lisa Schoyer; Beth Stronach; Anton M Bennett; Susan Blaser; Amanda Brown; Rebecca Burdine; Emma Burkitt-Wright; Pau Castel; Sandra Darilek; Alwyn Dias; Tuesdi Dyer; Michelle Ellis; Gregg Erickson; Bruce D Gelb; Tamar Green; Andrea Gross; Alan Ho; James Lloyd Holder; Shin-Ichi Inoue; Angie C Jelin; Annie Kennedy; Richard Klein; Maria I Kontaridis; Pilar Magoulas; Darryl B McConnell; Frank McCormick; Benjamin G Neel; Carlos E Prada; Katherine A Rauen; Amy Roberts; Pablo Rodriguez-Viciana; Neal Rosen; Gavin Rumbaugh; Anna Sablina; Maja Solman; Marco Tartaglia; Angelica Thomas; William C Timmer; Kartik Venkatachalam; Karin S Walsh; Pamela L Wolters; Jae-Sung Yi; Martin Zenker; Nancy Ratner
Journal:  Am J Med Genet A       Date:  2019-12-11       Impact factor: 2.802

Review 7.  Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.

Authors:  Valentina Sala; Simona Gallo; Christian Leo; Stefano Gatti; Bruce D Gelb; Tiziana Crepaldi
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

8.  Raf Kinases Are Essential for Phosphate Induction of ERK1/2 Phosphorylation in Hypertrophic Chondrocytes and Normal Endochondral Bone Development.

Authors:  Garyfallia Papaioannou; Elizabeth T Petit; Eva S Liu; Manuela Baccarini; Catrin Pritchard; Marie B Demay
Journal:  J Biol Chem       Date:  2017-01-10       Impact factor: 5.157

9.  Mechanisms of aneuploidy induction by RAS and RAF oncogenes.

Authors:  Tamihiro Kamata; Catrin Pritchard
Journal:  Am J Cancer Res       Date:  2011-03-29       Impact factor: 6.166

Review 10.  From Bench to Bedside and Back: Improving Diagnosis and Treatment of Craniofacial Malformations Utilizing Animal Models.

Authors:  Alice F Goodwin; Rebecca Kim; Jeffrey O Bush; Ophir D Klein
Journal:  Curr Top Dev Biol       Date:  2015-10-06       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.